Dr. Modeline Longjohn is a postdoctoral fellow in the Department of Anatomy & Cell Biology at
Western University. She is conducting BCC-funded breast cancer research under the
mentorship of Dr. Alison Allan.
- Could you share your motivation/personal connection to breast cancer research?
I am motivated by the suffering and pain that a breast cancer diagnosis can bring both to the
patient and their family and friends. I have experienced some of this pain due to my own
friends who have had breast cancer diagnoses. Specifically, two decades ago, I lost a close
family friend to breast cancer and lost another friend a decade later. In both cases, early
detection and better treatment options would have saved their lives. Therefore, every day I am
involved in breast cancer research, I do it as a tribute to those affected by breast cancer, and to
contribute towards a future where no one dies from breast cancer. - What specific areas of breast cancer research are you currently focusing on, and why are
they important?
My research is focused on triple negative breast cancer – the breast cancer subtype with the
worst outcome. This type of breast cancer has the tendency to spread (or metastasize) and
affects women from ethnic minorities more than other subtypes. In addition, triple negative
breast cancer currently has limited treatment options once it spreads. My research is focused
on investigating which proteins triple negative breast cancer cells may use to spread to
different organs such as the bone, brain, and lung. I am using a sophisticated technology called
proteomics to look at organ-specific protein changes, particularly in response to normal and
low oxygen, which can affect metastasis. The functions of the identified proteins will then be
tested using special assays, to understand their importance in breast cancer spread. In the
future, the results of this research could identify new ways to predict and manage the
preferential spread of breast cancer cells to specific organs. - What recent breakthroughs or discoveries in Canadian breast cancer research are exciting
to you?
A researcher at McGill University is currently working on developing new blood biomarkers for
monitoring response to therapy. This technique is called liquid biopsy. Using this method,
patients can be checked in real-time to ascertain if the treatment is working or not. This can
allow for a more tailored treatment plan instead of the traditional one-size-fits-all model, which
doesn’t work for every patient. I am excited about this, because my area of research could lead
to also developing new tools for liquid biopsy – specifically for predicting and managing cancer
spread, an area that desperately needs fresh solutions. - How do you see the future of breast cancer prevention, screening, diagnosis, treatment
evolving through research?
In my opinion, the future of breast cancer is liquid biopsy and precision/personalized medicine.
I envision the use of simple blood tests to detect breast cancer early, leading to more effective
screening and early diagnosis. Liquid biopsy will be used to develop a precise/personalized treatment plan, based on the patient’s biology/genetics, leading to much better outcomes. The research to make this possible is currently underway in labs across Canada (and globally), including at the Allan lab, where my research is taking place. - In your opinion, what role can public awareness and advocacy play in advancing breast cancer research and treatment?
Public awareness is essential for the public to have accurate information about screening, early detection, and symptoms to watch out for. Public advocacy is also important, as it facilitates the fundraising process (which provides much needed funding for cancer research), and promotes legislation that improves policies and modalities surrounding research and treatment.

















